|
| Press Releases |
|
 |
|
| Friday, March 13, 2026 |
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix(R)) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo |
| more info >> |
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix(R)) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo |
| On 12 March 2026, China Medical System Holdings Limited is pleased to announce that its subsidiary, Dermavon Holdings Limited has its innovative prescription medicine ruxolitinib phosphate cream (Lumirix(R)) (the "Product", marketed as Opzelura(R) in the U.S., Europe and Canada) recorded the initial prescriptions for vitiligo patients across 30 provincial-level regions. more info >> |
|
| Thursday, March 5, 2026 |
|
|
CMS (867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity |
| more info >> |
|
|
CMS (867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity |
| China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection ("CMS-D008") received the Drug Clinical Trial Approval Notice issued by National Medical Products Administration ("NMPA") on 4 March 2026. more info >> |
|
| Tuesday, February 24, 2026 |
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China |
| more info >> |
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China |
| CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China more info >> |
|
| Friday, January 30, 2026 |
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China |
| CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China more info >> |
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China |
| CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China more info >> |
|
| Wednesday, July 16, 2025 |
|
|
A New Chapter Begins! CMS Achieves Secondary Listing on the Singapore Exchange Main Board Today |
| more info >> |
|
|
A New Chapter Begins! CMS Achieves Secondary Listing on the Singapore Exchange Main Board Today |
| On the morning of 15 July 2025, China Medical System Holdings Limited ("CMS" or the "Group") rang the ceremonial bell to mark its official listing on the Singapore Exchange Main Board (Stock Abbreviation: CMS, Stock Code: 8A8). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
トヨタ、2025年度 販売・生産・輸出実績を発表
Apr 27, 2026 13:35: JST
|
|
|
三菱重工、採用情報サイトを全面リニューアル
Apr 27, 2026 12:00: JST
|
|
|
6 Ways to Avoid Hidden Fees When Spending Overseas
Apr 27, 2026 11:00 HKT/SGT
|
|
|
China Chunlai Announces 2026 Interim Results
Apr 27, 2026 10:23 HKT/SGT
|
|
|
中國春來公佈二零二六年中期業績
Apr 27, 2026 10:15 HKT/SGT
|
|
|
TuneFab、2026年ゴールデンウイークにあわせ対象製品を期間限定価格で提供～最大80%オフ
Apr 27, 2026 10:00: JST
|
|
|
Peer To Peer Network (OTC: PTOP) Targets Revenue Inflection Point with MOBICARD 1.8 Launch Expected Within 30 Days
Apr 25, 2026 07:03 HKT/SGT
|
|
|
EQIBank expands global, regulated Banking-as-a-Service platform for cross-border banking across fiat and digital assets
Apr 24, 2026 20:00: JST
|
|
|
EQIBank expands global, regulated Banking-as-a-Service platform for cross-border banking across fiat and digital assets
Apr 24, 2026 19:00 HKT/SGT
|
|
|
FastX Announces Its Launch, a New Generation Global Trading Exchange
Apr 24, 2026 13:00: JST
|
|
|
analytica Hanoi 2026 Makes Its Debut, Bringing the Global Science and Laboratory Platform to Northern Vietnam
Apr 24, 2026 12:05 HKT/SGT
|
|
|
FastX Announces Its Launch, a New Generation Global Trading Exchange
Apr 24, 2026 12:00 HKT/SGT
|
|
|
CMS (867.HK; 8A8.SG): NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China
Apr 23, 2026 22:00 HKT/SGT
|
|
|
Sisel International Appoints Pamela Ferry as General Manager of Australia and New Zealand to Support Regional Expansion
Apr 23, 2026 20:00: JST
|
|
|
康哲藥業：1類新藥MG-K10季節性過敏性鼻炎適應症NDA獲受理
Apr 23, 2026 19:48 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
